Simplify Asset Management Inc. Decreases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Simplify Asset Management Inc. cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 34.7% in the 4th quarter, HoldingsChannel reports. The fund owned 2,307 shares of the medical equipment provider’s stock after selling 1,228 shares during the quarter. Simplify Asset Management Inc.’s holdings in Zimmer Biomet were worth $244,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Dunhill Financial LLC grew its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet in the 4th quarter worth $25,000. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the third quarter valued at about $35,000. Kentucky Trust Co bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $39,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $40,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Royal Bank of Canada reduced their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Finally, Raymond James dropped their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.95% of the company’s stock.

Zimmer Biomet Trading Down 0.9 %

Zimmer Biomet stock opened at $110.79 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The business’s fifty day simple moving average is $106.74 and its two-hundred day simple moving average is $106.86. The company has a market capitalization of $22.05 billion, a price-to-earnings ratio of 24.90, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the business posted $2.20 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.